Detecting Chronic Diseases from Sleep-Wake Behaviour and Clinical Features by Fallmann, S. & Chen, Liming
Detecting Chronic Diseases from Sleep-Wake
Behaviour and Clinical Features.
Sarah Fallmann
School of Computer Science and Informatics
De Montfort University, Leicester, U.K.
Liming Chen
School of Computer Science and Informatics
De Montfort University, Leicester, U.K.
Abstract—Many chronic diseases show evidence of correlations
with sleep-wake behaviour, and there is an increasing interest
in making use of such correlations for early warning systems.
This research presents an approach towards early chronic disease
detection by mining sleep-wake measurements using deep learn-
ing. Specifically, a Long-Short-Term-Memory network is applied
on actigraph data enriched with clinical history of patients.
Experiments and analysis are performed targeting detection at
an early and advanced disease stage based on different clinical
data features. The results show for disease detection an averaged
accuracy of 0.62, 0.73, 0.81, 0.77 for hypertension, diabetes,
sleep apnea and chronic kidney disease, respectively. Early
detection performs with an averaged accuracy of 0.49 for sleep
apnea and 0.56 for diabetes. Nevertheless, compared to existing
work, our approach shows an improvement in performance and
demonstrates that predicting chronic diseases from sleep-wake
behavior is feasible, though further investigation will be needed
for early prediction.
Index Terms—Deep Learning, Chronic Disease Detection, Sleep
Monitoring.
I. INTRODUCTION
Chronic diseases are one of the main causes of deaths
and disabilities which is a major factor to the quality of
life of patients and relatives. With the growing ageing
population, the prevalence of chronic diseases will impact
more and more people. In addition, chronic diseases are also
a problem for the society as they produce high costs for
recovery and management [1]. Currently, chronic diseases
are under-diagnosed by a significant percentage, by using
the estimated effected patients against the once diagnosed;
hypertension 30− 40%, diabetes 20− 50% [2] and it is also
present in chronic kidney disease (CKD) [3] and obstructive
sleep apnea [4]. An easy, sensor-based and reliable method
for early diagnosis or prediction is still missing.
It is clinically observed that people suffering from chronic
diseases such as diabetes [5], [6], CKD [7], hypertension [8],
arthritis and stroke [6] usually have troubles with their sleep,
like difficulty falling/staying asleep and daytime sleepiness [6].
These correlations with sleep-wake behaviour can be used for
prediction of chronic diseases, which is investigated in the
presented approach. The differences are manifested in (1) the
actigraph sleep-wake patterns of the individuals, comprising
information of the sleep efficiency and sleep duration [9],
and (2) the clinical feature characteristics, such as body mass
index(BMI). The diagnosis and early detection of specific
chronic conditions and comorbidities can also later help in
the self-management process [1].
Diagnosis of chronic disease are currently based on (1) inva-
sive methods such as blood sugar screening for diabetes [10],
(2) symptoms, risk factors and clinical history or (3) sensor-
based, such as within a sleep clinic to diagnose obtrusive
sleep apnea [4] or with blood pressure measurements for
hypertension [11]. These methods can also be combined to
reach a fast and trustworthy result, for example, by combining
medical history, physical exam, and results from a sleep study
for OSA diagnosis [4].
For early detection, two main methods are presently used
(1) Marker-based clinical analysis and (2) sensor-based be-
havioural analysis.
In method (1), early detection of chronic diseases can be based
on bio-, neuropsychological- or structural-image-markers. Re-
search has been done on, e.g., Alzheimer’s disease [12],
diabetes [10] and CKD [3].
The second method (2) is based on data investigation coming
from sensors, such as an actigraph. Ju et al. [13] analysed
the role of sleep in early detection of Alzheimer’s disease
in humans based on β-amyloid(Aβ) and actigraph data. Aβ
is related to sleep quality and quantity. For participants with
low Aβ42, it showed a correlation with worse sleep quality.
Aggarwal et al. [14] investigated actigraph data from the
Hispanic Community Health Study [15] to detect sleep apnea,
insomnia, diabetes and hypertension. They applied a Convo-
lutional Neural Network (CNN) and presented a method for
embedding activities. The study has some limitations as such:
An imbalanced dataset, used for a supervised machine learning
approach, with the majority of subjects not suffering from
the disorders and a classification task to predict the disorder-
positive subjects. Their models and baselines are highly biased
towards predicting the majority class [14]. Actigraph data is
also used for exploring correlation of sleep behaviour disorders
between affected and non-affected chronic disease patients
such as Parkinson’s disease. This includes, for example, that
the total number of wake bouts is higher for Parkinson disease
patients affected by sleep behaviour disorders [16]. In a
later stage, this knowledge can potentially be used for early
detection of specific disease related symptoms and features,
and help during the diagnosis process. Time-series data based
diagnosis, in the field of recognising patterns in multivariate
time-series of clinical measurements, is presented in [17],
which has been a quite new approach, as previous studies
mostly applied neural networks in this context, but not Long-
Short-Term-Memory networks (LSTMs).
The paper contributes to the literature in three folds. Firstly,
we apply the Long-Short-Term-Memory networks (LSTMs)
which, in contrast to previous work, can deal with the temporal
aspects of the actigraph data. Secondly, we fuse actigraph
and clinical history data of individuals, introducing a multi-
dimensional feature vector. Thirdly, we experimented and
analysed multiple use scenarios, including the good and bad
classified patients based on significant difference of clinical
features. Through these novel approach and experimental
studies, we address the challenges for chronic disease detection
and limitations from previous work.
The paper is structured in the following way. In Section II
the approach for the chronic disease recognition is described,
including the initial method configuration. The dataset is
described and the experimental settings are given. Section III
presents the results which are described and discussed. Sec-
tion IV concludes the detection approach and describes pos-
sible future extensions.
II. METHOD AND MATERIALS
In this section, an approach is proposed to diagnose and
early detect chronic diseases based on sleep-wake behaviour
and clinical history data. Furthermore, the method design and
configuration using the time-series classification algorithm are
presented. The dataset used for investigating the approach and
the settings of the experiments are given.
A. Learning Model Design and Configuration
The approach is a time-series data classification. Time-series
data are data which have time dependency, in our case those
are activity counts and white light data from six consecutive
days. Activity counts give the intensity of activeness over
time. White light is an actigraph feature which can tell the
level of darkness or lightness at a specific time, helping to
judge the day-night-rhythm, further details can be found in
Section II-B. A prominent deep learning method in the field of
time-series data classification is a deep Neural Network, called
Long-Short-Term-Memory networks (LSTMs). This method
was first introduced by Hochreiter and Schmidhuber [18]
in 1997, extended over time mainly by additions of forget
gates [19], and peep-hole connections [20]. Application in the
field of diagnosis of multiple time-series data already showed
successful [17], following an architecture described by Graves
et al. [21].
In this paper, a LSTMs approach is followed using the
architecture presented in Fig. 1. This contains an embedding
based on word-2-vec for the activity count and white light
data. Embedding is able to extract useful features to represent
similarities and relationships within data. Words are translated
into a vector representation [22], [23]. Here, activity counts
and white light data are interpreted as words. The embedding
method provides features used as input for LSTMs [22], [23].
Clinical history data are further sources of information used as
direct input. Clinical history data include clinical knowledge
of the person such as BMI level or Family History of Diabetes,
details on the features used can be found in Section II-B. The
combination of actigraph data enriched with clinical history
data from individuals is used as input for three LSTMs layers
each using a dropout strategy for training, followed by a
dense layer to flatten and fully connect. Dropout is used to
ignore neurons during the training phase to prevent overfitting
[24]. The fraction of dropout can be set between 0.0 (no
dropout) to 0.9. For example setting the dropout rate to 20%
means that two in ten inputs will be randomly excluded.
Dense layers apply a matrix-vector multiplication resulting
in a transformation of the data into a lower dimensional
feature vector. The last step is a softmax activation, which
normalises scores to probabilities for classification of two or
three classes, whereas two classes are (a) disease affected
and (b) non-specific-disease-affected and 3 classes are (a)
pre-disease-, (b) disease- and (c) non-specific-disease-affected.
The two classes problem implements the disease detection
distinguishing affected and non-affected individuals whereas
the three classes problem deals with early disease detection
distinguishing affected, early stage and non-affected.
Fig. 1: The LSTMs method architecture for disease detection.
Initial experiments let us choose the following layer sizes:
1st layer input size is [400+clinical data features] and output
size 200, 2nd layer input 200 and output 100, and input of
100 and output of 50 for the 3rd layer. Furthermore, the
combination of a dropout rate of 0.2 and batch-size allowing
training per person is used, compare Fig. 4 and Section II-C.
The model fitting was investigated with an adam optimisation
method [25] as initial experiments ruled out Root Mean Square
Propagation for our study. Embedding size was empirically
set to 200, where only the activity levels and white light data
are embedded. This makes it possible to represent the data
sequence (e.g. 240) in a feature vector [23] with size 200,
creating an input vector for the LSTMs of size 400+clinical
data features, consisting of 200 features for activity counts,
200 features for white light and the clinical data features
different for each disease, see details in Section II-B. The
Training Process was stopped when the loss did not decrease
within 8 intervals, with a maximum of 50 epochs.
B. Dataset and Processing
The data used to show the possible improvement by using
the established approach, was made available by the National
Sleep Research Resource [26] and includes clinical history
and actigraph measurements from 2,252 participants with
different disorders such as hypertension, apnea, diabetes and
CKD. Clinical history includes information about an indi-
vidual such as BMI level or Family History of Diabetes.
The participants were instructed to wear wrist-worn actigraph
devices (Actiwatch Spectrum, Philips Respironics) for a week.
Records were scored by a trained technician at the Boston
Sleep Reading Center [26] and specific algorithms, deriving
parameters such as wake/sleep patterns and activity levels.
Actigraph data are available per 30 seconds, which make 2880
values per day. The data of six consecutive days per person
are used for analysis in this study, as not all participants have
seven full days of data. This is necessary to provide a balanced
dataset for training purposes. Initial results show that using
the same amount of data for each individual results in better
outcomes, which was also the case for Aggarwal et al. [14].
The proof of concept is investigated for four different chronic
diseases and conditions: (1) diabetes, (2) hypertension, (3)
CKD and (4) sleep apnea. These are divided into three differ-
ent classes each, which are (a) non-specific-disease-affected
(b) pre-disease (early stage) and (c) disease-affected, compare
Fig. 2(a). For hypertension only two classes are available.
(1) Diabetes is characterised by hyperglycemia [27]. Pre-
diabetes is classified over the elevation of plasma glucose
above the normal range but below that of clinical diabetes [27].
People affected by diabetes are more likely to have trouble
sleeping, caused by the glucose level which is influencing
sleep. Furthermore, lethargy and insomnia can be caused by
diabetes [28].
(2) Hypertension is defined by an abnormal blood pressure
(≥ 140/90) [11]. Sleep and hypertension are correlated, in
more detail, habitual short sleep duration is associated with
hypertension. Insomnia is correlated with increased hyperten-
sion risk [8].
(a)
(b)
Fig. 2: (a) The number of people per disease divided by
not-specific-disease affected, mildly affected and affected. (b)
Multi-morbidities in the dataset based on diabetes, apnea,
CKD and hypertension.
(3) CKD is a severe health problem, which is defined as
kidney damage over glomerular filtration rate (GFR). Five
stage classification is based on the level of GFR [3]. In
this experiments, only stage one and two are investigated.
A wide range of symptoms affects the patients leading to
e.g., fatigue, sleep disturbances, restless legs and increase in
urination mostly during the night [7].
(4) Obstructive sleep apnea is classified by upper airways
becoming blocked repeatedly during sleep [4]. The classifi-
cation is based on the Apnea/Hypopnea Index (AHI), where
the numeric events per hour are given. In the concrete use-
case, >4% oxyhemoglobin desaturation is used for the AHI.
These can occur less than 5 times per hour resulting in no
apnea, between 5 and 15 times per hour classified as mild
apnea, between 15 to 30 times resulting in moderate apnea
and severe apnea with occurrences over 30 times per hour [4].
In the test case three groups where used, which are none, mild
and moderate-severe.
In Fig. 2(b) the number of people in the dataset with more than
one disease and the combination of which is given. Showing
combination of diseases like apnea and diabetes, diabetes and
hypertension and others. Different multi-morbidities are shown
to be more present than others and therefore can influence the
classification, as the non-specific-disease-affected classified
people, can potentially be affected by another disease.
To give an overview of the data and the individual differences,
between affected and non-affected patients a circle plot is
given for diabetes, compare Fig. 3. The plots show activity
count data (green) over the intervals of being awake (grey) and
asleep (red) over 7 consecutive days. The yellow describes not
available data due to differences in the end times. The plots
illustrate non-diabetic-affected Fig. 3(a) and diabetes-affected
Fig. 3(b). The images show the already affected and not mild
or pre-stage affected individuals. The images should be seen as
an example of individuals classified correctly by the algorithm.
Be aware of, that there are personal differences between
individuals as well, but general conclusions can be drawn for
specific disease groups, as the results show in Section III. The
use of disease-affected and non-specific-disease-affected is a
real world approach. It needs to be mentioned that this can
result in a group which are not affected by the specific disease,
but can also not be classified healthy, as they can for example
not be affected by apnea, but still be affected by diabetes, as
multi-morbidities are common, compare Fig. 2(b).
(a) Not-affected by diabetes (b) Affected by diabetes
Fig. 3: Acitivty count data of seven days from individuals,
affected by diabetes and non-affected, shown in green and
showing the wake and sleep patterns in red and grey.
Preprocessing includes extraction of individuals and data of in-
terest coming from (1) actigraph data, including activity levels
and white light and (2) clinical data, including BMI, family
history of diabetes and affected by hypertension, diabetes or
asthma. Activity levels and white light data are used for all
disease-specific tasks and specific clinical data parameters
are used for each disease. For CKD, risk factors contain
diabetes, high blood pressure as well as obesity [29] and
therefore are included as clinical history information (BMI,
diabetes and hypertension). For apnea, comorbidities usually
are obesity, diabetes and hypertension and sometimes asthma
[30], therefore those are included (BMI, asthma, diabetes,
hypertension). For diabetes the family history of diabetes is
important and obesity [31] (BMI, diabetes family history).
Hypertension is affected by obesity and is a risk factor for
diabetes [32], [33] so correlated and included in the clinical
history information (BMI, diabetes).
Furthermore, the data is normalised for training and testing
during the classification process.
C. Experiment Design and Implementation
In this paper, a LSTMs approach is followed and compared
based on training and test performance in different experiments
and compared with an existing method from [14] which
used CNN. The main improvement is reached by introducing
disease-specific features coming from clinical data history
based on important relations from literature, compare Sec-
tion II-B.
LSTMs parameters were adjusted empirically by initial exper-
iments, details can be found in Section II-A. To reach training
per person the batch-size for training and testing is six, as
six days per individual are available. Splitting the daily data
from 2880 sequence length (dimension for one day 2880x1)
into 180 (dimension for one day 180x16) or 240 (240x12)
implies a batch-size training rate of 96 (16*6) or 72 (12*6),
respectively, compare Fig. 4. This guarantees a training per
person approach which means 6 days per person. Sequence
length of 2880(one day) was not further used, based on the
long training time and no increase in accuracy.
Fig. 4: Training batch size transformation for the example of
180 sequence length.
The first experiment investigated the best sequence length. The
sequence lengths tested are 180 and 240 for each disease-
specific classification for 2 and 3 classes.
The repeated wrong classification of certain participants sug-
gests investigating the wrong classified participants in more
detail to extract differences in those. Those differences can be
seen as potential sources for misclassification which can be
used as additional information for improving the classification
approach. The statistic counts for non-specific-disease-affected
wrong/correct-classified and disease-affected wrong/correct-
classified are given. Wrongly classified are those which are
more than two times wrong classified during testing. The
investigation concentrates on the best model outcome. The
second experiment classifies the significant different clinical
data parameters from the wrong and correct classified disease-
affected individuals during the test. The clinical data was
investigated in more detail with an independent two samples
t-test, for different means, variances, and sample size. Here,
the independent variable is disease-affected correct-classified
from disease-affected wrong-classified, and the dependent
variable is one of 38 clinical data parameters pre-decided
from the available variables in the dataset [26], [34]. Using
a significance level of 5%, different number of clinical data
parameters can be extracted being significantly different from
the disease-affected correctly classified from those wrongly
classified. These are given with the p-value of the statistical
test. Those clinical parameters include among others BMI,
Family History of Diabetes and Hypertension.
The third experiment investigated the possible improvement
which can be reached by including the knowledge of having
6 days of data per person. This is done in two ways based
on (1) counts and (2) average. The data per person as for
sequence length 180 is 96. (1) counts how often which class
is classified between e.g. intervals of length 96 and the one
with the highest amount, or the first one in the list if there are
two, is reassigned to the whole interval to 96 values. (2) takes
the average of the interval using a threshold of 0.5.
Furthermore, the outcomes of the best experiment, based on
the sequence length experiment, are compared with available
related work results from [14]. Task-specific means the models
are trained end-to-end for the disorder task at hand, whereas,
multi-task learning models, are trained jointly with all the
disorder prediction tasks learnt jointly (in the case of [14]
those are insomnia, apnea, diabetes and hypertension).
The experiment results show the averaged outcome for each
experiment which follows a leave-n-people-out approach. The
value n is 10% of the available disease affected individuals
for each disease-specific classification: diabetes, hypertension,
apnea and CKD. This means a 10-fold-cross-validation for
participants is conducted, with training on 90% of the data
and testing on 10%. Furthermore, each experiment is repeated
six times. These are 60 validation performances. Per fold the
best ’area under the curve(AUC)’ and best ’accuracy’ of all
epochs are chosen to give a 10-fold average outcome, which
is averaged over the six repeats. The reported outcomes are
accuracy, precision, recall, F1-score and AUC.
Experiments are the following: (1) Disease detection based
on a two classes problem for apnea, CKD, hypertension and
diabetes, which detects disease affected by using different
sequence lengths. (2) Early disease detection for diabetes
and apnea, which detects early stage and disease affected
resulting in a 3 classes classification problem, testing different
sequence lengths. (3) Significant clinical data features for
wrong and correct classified disease-affected individuals. (4)
Improvement of accuracy by including knowledge of six days
of data per person and (5) Comparison of our results to
available related work results.
III. RESULTS AND DISCUSSIONS
In this section, the results of the different experiments are
presented for disease and early disease detection. Furthermore,
results are described, discussed and limitations are examined.
A. Disease Detection
In summary, the disease detection shows overall good out-
comes for diabetes, apnea and CKD. For hypertension the
general outcome is less promising, see Table Ib and IV,
compared to the results in [14] no improvement in accuracy
can be seen, but in precision, recall and F1-score. For apnea
detection our approach can outperform the results with CNN,
compare Table IV. The results of the 2 classes experiments are
compared to the results from [14] for hypertension and apnea.
Diabetes Experiments on averaged AUC and accuracy show
that for the case of diabetes similar results can be achieved
with sequence length of 240 and 180 resulting in an AUC of
0.76(±0.02) and accuracy of 0.71 for 240. A higher standard
deviation can be seen for 240 in comparison to the 180 case
for averaged accuracy, compare Table Ia. Therefore, the best
outcome is classified as the 180 sequence length case for
averaged accuracy.
For diabetes detection, 120 disease-affected individuals are
wrongly classified as non-specific-disease-affected over all
tests and 205 are correctly classified as disease-affected. For
the non-specific-disease-affected participants, 107 are wrongly
classified from randomly picked 325 individuals from all non-
specific-disease-affected participants in the dataset. In Table II
three variables have been shown to be significantly different
in the disease-affected case comparing correct classified and
wrong classified. Those are BMI, Family History of Dia-
betes and Pneumonia. These features are affecting the wrong
classified features. The group that is wrongly classified has
apparently (1) a higher average BMI with 33.3 than the group
that is usually correctly classified with 31.6, (2) the average
family history of diabetes is 0.9 in contrast to 0.5 for correctly
classified and (3) for pneumonia the average of appearance is
0.22 and 0.12 for correctly classified.
The results can be improved when the knowledge of training
and testing per person is used. This means the data structure,
of 6 days of data per person. This results in an increase of
accuracy by around 1% to 72.5 and 72.7 percent for 180
and 240, respectively, making the combined scores the best
optimisation technique for this case, compare Table III.
Hypertension Comparison with the already performed exper-
iments of [14] in Table IV shows that the LSTMs approach
improves the precision, recall and F1-score, but can reach
TABLE I: Experiments for different sequence lengths are given for the tested chronic diseases. Each table show the averaged
cross-validation outcome for precision(P), recall(R), F1-Score, Area under the curve(AUC) with Standard deviation(SD) and
accuracy(acc), for averaged accuracy and averaged AUC, compare Section II-C.
(a) Diabetes
size avg P R F1 AUC(SD) acc
180 acc 0.70 0.77 0.73 0.75(±7E-3) 0.71
180 AUC 0.69 0.74 0.70 0.76(±7E-3) 0.69
240 acc 0.69 0.79 0.73 0.76(±0.02) 0.71
240 AUC 0.67 0.77 0.72 0.77(±0.02) 0.69
(b) Hypertension
size avg P R F1 AUC(SD) acc
180 acc 0.60 0.64 0.61 0.60(±0.01) 0.60
180 AUC 0.58 0.60 0.58 0.60(±0.01) 0.58
240 acc 0.58 0.60 0.58 0.56(±2E-3) 0.58
240 AUC 0.55 0.57 0.55 0.57(±2E-3) 0.55
(c) Apnea
size avg P R F1 AUC(SD) acc
180 acc 0.82 0.77 0.78 0.82(±0.05) 0.79
180 AUC 0.79 0.75 0.76 0.85(±0.05) 0.77
240 acc 0.83 0.75 0.78 0.81(±0.07) 0.79
240 AUC 0.81 0.70 0.74 0.84(±0.07) 0.76
(d) Chronic Kidney Disease
size avg P R F1 AUC(SD) acc
180 acc 0.80 0.71 0.73 0.72(±0.15) 0.75
180 AUC 0.75 0.63 0.66 0.78(±0.15) 0.69
240 acc 0.79 0.62 0.67 0.68(±0.07) 0.71
240 AUC 0.74 0.55 0.59 0.73(±0.07) 0.66
TABLE II: Significant parameters analysis outcome of the
independent 2-sample t-test are given for each disease, based
on the disease-affected wrongly and correctly classified indi-
viduals.
disease parameters(p-value)
diabetes BMI(0.02) Fam. Hist. Diab.(2.1E-09)
Pneumonia(0.018)
hypert. BMI(1.8E-17) Total Drinks per Week(0.012)
Apnea/Hypopnea Index(4.8E-05) Treatment of Hypert.(0.013)
Alcohol Use (0.028) Physical Activity Level(0.036)
apnea BMI(2e-3) 4-level Hypertension(3E-3)
Hypertension(1E-3) 3-level Diabetes(0.04)
Diabetes Diag.(0.025) Antidiabetics(0.036)
Antihypertensives(0.025) Cigarette Use(0.017)
Hypertension Treatment(0.015)
CKD BMI(0.032) Antihypertensives(0.025)
Hypertension(1.4E-3) Treatment of Hypert.(0.012)
Airflow Limitation(0.044) Physical Activity Level(0.043)
4-level Hypert.(0.021) Stroke(0.036)
TABLE III: Accuracies using the knowledge of 6 days per
person. Each table shows the accuracy(acc), the accuracy cal-
culated by using the highest count of labels per person(counts)
and the best score per person(average), details can be found
in Section II-C.
disease size acc counts average
diabetes 180 0.714 0.725 0.725
240 0.712 0.726 0.727
hypert. 180 0.603 0.615 0.620
240 0.578 0.587 0.589
apnea 180 0.794 0.813 0.810
240 0.791 0.808 0.800
CKD 180 0.750 0.756 0.767
240 0.709 0.728 0.722
only similar accuracy for sequence length 180 for the multi-
task case. These results can come from the fact that the used
TABLE IV: Comparison Task-specific and Multi-task from
[14] with our results from apnea, hypertension and diabetes.
experiment model precision recall F1 acc
HYPERTENSION
task-spec CNN 0.44 0.31 0.37 0.69
multi-task CNN 0.48 0.41 0.44 0.61
180 LSTM 0.60 0.64 0.61 0.60
240 LSTM 0.58 0.60 0.58 0.58
APNEA
task-spec CNN 0.31 0.63 0.42 0.55
multi-task CNN 0.40 0.48 0.43 0.68
180 LSTM 0.82 0.77 0.78 0.79
240 LSTM 0.83 0.75 0.78 0.79
DIABETES
task-spec CNN 0.40 0.51 0.45 0.41
multi-task CNN 0.46 0.47 0.46 0.44
180 LSTM 0.44 0.58 0.50 0.47
240 LSTM 0.44 0.57 0.51 0.48
embedding is not designed for activities, but for words.
Overall, we can see that hypertension is the least well perform-
ing classification in the 2-class-problem, compare Table Ib.
The best outcome is achieved with 180 with an accuracy and
AUC of 0.60, with very little variation, which suggests that
specific groups cannot be detected. This suggests investigating
the wrong classified participants in more detail to extract
differences in those. The investigation showed that those which
are more than two times wrong classified with sequence length
180 is 143 over all tests and 332 being correct classified as
disease-affected. For the non-specific-disease-affected partic-
ipants, 126 are wrong classified from randomly picked 475
used from all non-specific-disease-affected participants. Using
a significance level of 5%, six variables have been shown to
be significant different between the disease affected correct
classified from those wrong classified. Those are BMI, Total
drinks per week, AHI, Treatment of Hypertension, Alcohol
Use and Physical activity level, compare Table II. These
features are affecting the wrong classified features. The group
that is wrongly classified has apparently differences in the
average of the features: (1) higher BMI 34 than correctly
classified with 30, (2) lower Total drinks per week 1.28
compared to 2.56, (3) higher AHI 7.5 compared to 3.9 (4)
higher Treatment of Hypertension 0.62 compared to 0.5 (5)
lower Alcohol Use 2.05 compared to 2.23 and (6) higher
Physical activity level 2.52 compared to 2.4.
An improvement of 1-2% in accuracy can be seen when using
the combined scores method for the accuracy, resulting in
0.59(240) and 0.62(180) accuracy, see Table III.
Sleep Apnea The best outcome for sleep apnea can be reached
using averaged accuracy resulting in a similar outcome for se-
quence length of 180 and 240, compare Table Ic. An accuracy
of 0.79 can be reached and an AUC of 0.82. The investigation
showed that the wrongly classified as non-specific-disease-
affected are 23 and 62 being correctly classified as disease-
affected. For the non-specific-disease-affected individuals, 13
are wrong classified from 85 randomly picked from all non-
disease participants. Those wrong/correct classified from the
disease affected group have a significant difference in the fol-
lowing variables: BMI, 4-levels Hypertension, Hypertension,
Hypertension Treatment, 3-levels Diabetes, Diabetes Diagno-
sis, Antidiabetics, Antihypertensives and Cigarette Use, see
Table II. The group that is wrongly classified has differences
in the average of the features: (1) higher averaged BMI of 38
than correctly classified with 33, (2) higher 4-level grouped
Hypertension 3 compared to 2.3, (3) higher Hypertension
0.8 compared to 0.4 (4) higher 3-level grouped Diabetes 2.3
compared to 2.0 (5) lower Diabetes Diagnosis 2.2 compared
to 2.6, (6) lower Antidiabetics 0.27 compared to 0.07, (7)
higher Antihypertensives 0.47 compared to 0.2, (8) higher
Cigarette Use 1.9 compared to 1.5 and (9) higher Hypertension
Treatment 0.6 compared to 0.3.
An improvement of accuracy is depicted in Table III with
the combined amount technique reaching 0.813 and 0.808 for
180 and 240, respectively. In comparison, the results of [14]
in Table IV can be improved considerably by using LSTMs
from an accuracy 0.68 (CNN) to 0.79 (LSTM) and precision
even from 0.40 (CNN) to 0.82(180), 0.83(240) (LSTM).
Chronic Kidney Disease For CKD detection the best model
can be classified as the 180 model with an accuracy of 0.75
and AUC of 0.72, compare Table Id. Receiver Operating
Characteristic curves were interpreted and showed a higher
standard deviation for the individual True Positive rates, which
represents the higher differences in epochs and folds. An
improvement for accuracy can be reached for the sequence
length 180 with the combine score technique towards 0.767
and for the 240 sequence length with the combined amount
reaching 0.728, compare Table III.
The investigation showed that the wrongly classified for
sequence length 180 are 17, and 43 being correct classi-
fied as disease-affected. For the non-specific-disease-affected
participants 11 are wrong classified. 8 variables have been
shown to be significant different. Those are BMI, Antihyper-
tensives, Hypertension, Treatment of Hypertension, Airflow
limitation, Physical activity level, 4-level grouped hyperten-
sion and Prevalent Stroke (self report), compare Table II.
Those present features are potentially more than in the other
diseases, because of the less available data. Differences in
the average for wrong/correct classified are as follows: (1)
higher averaged BMI of 35 than correctly classified with 30,
(2) higher 4-level grouped hypertension 2.9 compared to 2.3,
(3) higher hypertension 0.8 compared to 0.4 (4) lower Airflow
limitation 0 compared to 0.1 (5) higher Physical activity level
2.6 compared to 2.3, (6) higher Prevalent Stroke 0.3 compared
to 0.03, (7) higher Antihypertensives 0.6 compared to 0.3 and
(8) higher Treatment of Hypertension 0.7 compared to 0.3.
B. Early Disease Detection
The early detection experiments show the outcomes of the 3-
classes problem, differentiating non-disease, pre-disease and
disease affected. As the standard deviation of CKD was
already high for the 2-classes problem, we concentrated on
diabetes and sleep apnea. The experimental outcomes show
the possibility of early detection. The results should be seen
as preliminar, which can further be improved and investigated
with experiments including further features or other classifi-
cation models.
Diabetes In Table IV the 3-classes problem of Diabetes
is compared to the related work in [14], showing that our
approach can reach an improvement of 3-7% in accuracy from
0.41 (CNN: Task-specific), 0.44 (CNN: Multi-task) to 0.47
(LSTM:180), 0.48 (LSTM:240) and also recall and F1 show
an improvement overall. Precision has similar outcomes.
For early detection of diabetes similar outcomes can be
achieved for sequence length of 180 and 240, resulting in
averaged accuracy of 0.47 (180) and 0.48(240), and averaged
AUC of 0.63 (180) and 0.61 (240), compare Table Va. The
accuracy can be improved towards 0.48(180) and 0.49(240)
with the count method.
Sleep Apnea For sleep apnea the best results can be achieved
with sequence length 240 with an averaged accuracy of 0.54
and an averaged AUC of 0.61, compare Table Vb. The
accuracy can be improved towards 0.55(180) and 0.56(240)
with the count method. The individuals which are repeat-
edly wrong classified for the pre-disease-affected are 9,
disease-affected are 24 and non-specific-disease-affected are
18. Overall 85 individuals per group are used for training.
The features which are significantly different for the disease-
affected wrong/correct classified are: BMI (p-value:0.012),
Antihypertensive (0.028), Hypertension (0.0018), Hyperten-
sion Treatment (0.029), 3-level Diabetes (0.049), Diabetes
TABLE V: Sequence lengths experiments for early disease detection with a multi-class analysis approach, using one class
against the others; e.g., C1 describes C1 against all other classes; C1 is non-disease, C2 disease-affected, C3 pre-disease; avg.
describes the average over all classes and all repeats.
(a) Diabetes.
size precision recall F1 AUC(Std dev.) acc
C1 C2 C3 avg C1 C2 C3 avg. C1 C2 C3 avg. C1 C2 C3 avg.
180 0.48 0.49 0.35 0.44 0.58 0.59 0.50 0.58 0.53 0.56 0.34 0.50 0.66 0.66 0.51 0.62 0.47
240 0.48 0.50 0.35 0.44 0.58 0.60 0.51 0.57 0.53 0.58 0.35 0.51 0.65 0.67 0.53 0.62 0.48
(b) Apnea.
size precision recall F1 AUC(Std dev.) acc
C1 C2 C3 avg C1 C2 C3 avg C1 C2 C3 avg C1 C2 C3 avg
180 0.59 0.55 0.37 0.48 0.57 0.56 0.46 0.57 0.58 0.66 0.34 0.56 0.71 0.68 0.49 0.63 0.53
240 0.56 0.49 0.38 0.46 0.56 0.55 0.47 0.56 0.59 0.50 0.30 0.52 0.69 0.64 0.49 0.61 0.54
Diagnosis (0.019), Family History of Diabetes (0.038), Pneu-
monia (0.017) and 4-level Hypertension (7.6e-4). The group
that is wrongly classified disease-affected has differences in
the average of the features to the correctly disease-affected
classified: (1) higher averaged BMI of 38 compared to 34,
(2) higher Antihypertensive 0.5 compared to 0.2, (3) higher
Hypertension 0.8 compared to 0.4, (4) higher Hypertension
Treatment 0.58 compared to 0.3, (5) higher 3-level Diabetes
2.4 compared to 2.0, (6) higher Family History of Diabetes 0.7
compared to 0.4 and (7) higher Pneumonia 0.3 compared to
0.04 and (8) higher 4-level Hypertension 3.0 compared to 2.3.
We can see that similar features are significant in the 2-classes
apnea problem.
Overall, we can conclude that the pre-disease condition is
harder to classify. The early detection seems to be complex and
in need of further insight with more features or data sources.
Potential sources could be information from polysomnography
and clinical data features being significant different in the
wrong/correct classified cases.
C. Limitations
Limitations are the usage of pre-defined embedding function
and the missing evaluation of different loss functions. Initial
experiments predefined embedding showed good results and
was used for further investigation. The used word-2-vec em-
bedding method can be improved by using a designed act-
2-vec method as presented in [14]. Based on literature the
categorical cross-entropy approach was used for classification,
but others were not tested.
The decision was made to use the same amount of data
for each individual, as in 6 days each. Due to this decision
a limitations arise, as (1) some individuals can have a full
weekend in their dataset and some just one day and (2) not
all participants have the same consecutive days sequence,
which can lead to difficulties during the training phase of the
classification algorithm.
The significant feature analysis for the early disease detection
could give more insight by grouping the individuals which
are wrong-classified into two groups, wrong-classified as (1)
non-specific-disease-affected and (2) pre-disease-affected.
IV. CONCLUSION AND FUTURE WORK
This paper has investigated the hypothesis of chronic disease
detection based on the correlations between sleep-wake be-
havior and chronic diseases. An LSTM algorithm was applied
fusing actigraph data with clinical features, leading to a multi-
dimensional feature vector for effective disease detection.
We have tested and evaluated various use case scenarios,
including 2-classes disease detection problems (non-specific
disease versus disease affected) and 3-classes early disease
detection problems (non-specific-disease-affected, early stage,
and disease-affected), for four typical chronic diseases, as
such, hypertension, diabetes, sleep apnea and chronic kidney
disease. The approach is showing promising results, varying
for different use cases, resulting from existing differences in
chronic diseases characteristics. As assumed, there exists not
an one-size-fits-all approach for all types of chronic diseases,
but using specific clinical features per disease can deal with
the existing different characteristics to a certain extent.
Our future research will drill-down to discover which other
chronic diseases can be detected using sleep-wake behavior
analysis, and why some of them work less accurate. For
different chronic diseases what are the salient features as well
as what clinical data play a more significant role in helping
disease detection.
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